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Abstract
Background: We have previously reported that the defibrillation success rate of intravenous nifekalant
hydrochloride (NIF), a pure IKr-channel (IKr: the rapid components of the delayed rectifier potassium
current) blocker, was more than 75% for lidocaine--resistant ventricular tachycardia and fibrillation
(VT/VF) in patients with out-of-hospital cardiopulmonary arrest (CPA). However, there was no
effective treatment for the remaining 25% of patients in whom defibrillation was unsuccessful. We
hypothesised that the combination therapy of NIF and left stellate ganglion block (LSGB) was useful for
defibrillation in NIF-resistant VT/VF and investigated its efficacy in a retrospective study.
Methods and results: We investigated sequentially 272 out-of-hospital CPA patients treated
at Tokai University between April and December 2006. VT/VF occurred in 55 patients on
arrival or during cardiopulmonary resuscitation (CPR). On the basis of our CPR algorithm,
NIF was administered (0.15–0.3 mg/kg, i.v.) after the first direct-current cardioversion.
NIF-resistant VT/VFs were observed in 15 out of 55 patients and LSGB was performed on
11 of these with administration of NIF. Sinus rhythm was restored in 7 patients following
LSGB (64%) and complete recovery was achieved in 2 patients. In the non-LSGB group,
however, all the patients died.
Conclusions: The combination therapy of intravenous NIF and LSGB was useful for defi-
brillation in intractable VT/VF. It is a potential and innovative treatment strategy for
IKr-channel blocker resistant VT/VF. (Cardiol J 2007; 14: 355–365)
Key words: combined therapy, nifekalant hydrochloride, left stellate ganglion
block, out-of-hospital cardiopulmonary arrest, ventricular tachycardia,
ventricular fibrillation
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Introduction
Intravenous nifekalant hydrochloride (NIF),
a pure IKr-channel blocker (IKr: the rapid compo-
nents of the delayed rectifier potassium current),
has been developed in Japan and has been used to
treat patients with intractable ventricular tachycar-
dia and fibrillation (VT/VF) instead of intravenous
amiodarone (AMD), since the use of the latter has
not been permitted in Japan. There are several clin-
ical reports describing the effectiveness of NIF
since its release in 1999 [1, 2]. It has been known
to prolong significantly the refractory period [3] and
decrease the defibrillation threshold [4]. A recent
experiment using rabbit hearts has revealed one of
the mechanisms involved in the early termination
of spiral-type re-entrant VT by NIF [5]. The role of
NIF as a first-line drug for patients of acute coro-
nary syndrome (ACS) [1], electrical storm (ES) [6]
and out-of-hospital cardiopulmonary arrest (CPA)
[3, 7] has been established. However, no effective
treatment for NIF-resistant intractable VT/VF has
been available. We have reported that the defibril-
lation success rate of NIF was superior (> 75%) for
intravenous lidocaine-resistant VT/VF in patients
with out-of-hospital CPA. However, in the remain-
ing 25% of cases it was unsuccessful. This situa-
tion must be addressed with urgency in order to
establish another effective therapy for the manage-
ment of intractable VT/VF.
It has been known that dispersion in refracto-
riness between the ischemic border zone and the
normal zone is increased by left stellate ganglion
(LSG) stimulation in an ischemic dog model, and
this may enhance the opportunity for VF to occur [8].
In contrast, from the 1970s there have been many
experimental and clinical reports concerning the
anti-arrhythmic effect of blockade of the LSG
(LSGB) for re-entrant fatal tachycardia [9, 10]. It
has been reported that in humans sympathetic
blockades are superior to conventional anti-arrhyth-
mic therapy recommended by the advanced life sup-
port guidelines for the treatment of ES in recent
myocardial infarction (MI) [11]. Although there are
two methods for achieving sympathetic blockade,
namely LSGB and the administration of an intrave-
nous beta-blocker, LSGB was thought to be more
suitable and safer than a beta-blocker for cardiop-
ulmonary resuscitation (CPR), because the hemo-
dynamic changes after LSGB were considered to be
small, even during congestive heart failure [12]. We
therefore hypothesised that a sympathetic blockade
would combine the therapeutic effects of a pure IKr
blocker and reinforce the defibrillation effect
achieved by a single application of NIF. The aim
of this study is to investigate the efficacy of the
combination therapy of NIF and LSGB for patients
with sustained VT/VF in out-of-hospital CPA.
Methods
Subjects and methods (Fig. 1)
A total of 272 out-of-hospital CPA patients
were admitted to Tokai University Hospital be-
tween April and December 2006. Fifty-five patients
manifested VT/VF on arrival or during CPR, while
217 patients manifested asystole or pulseless elec-
trical activity (PEA). Electrical defibrillation was
successful in 6 patients by using biphasic direct-
current (DC) cardioversion alone, and 34 cases of
shock-resistant VT/VF were restored by using NIF
with DC cardioversion. The remaining 15 patients
manifested NIF-resistant VT/VF, which was either
recurrent or intractable. Of these 15 patients
11 underwent LSGB accompanied by additional
NIF administration, while 4 patients did not under-
go LSGB at the discretion of the attending physi-
cian because of the internal hemorrhagic risk of
puncture and the cervical anatomical anomaly. One
patient showed a decrease in platelets, 2 patients
were taking anticoagulants and 1 patient had exten-
sive old scarring of the skin structure around the
neck caused by a past history of the facial burn.
The research was conducted after obtaining the
approval of the Ethical Review Board. Sufficient
consideration was given to the ethical and safety as-
pects during the study. CPR was performed accord-
ing to the algorithm developed in Tokai University
(Fig. 1) on the basis of the 2005 American Heart
Association guidelines. Asystole and PEA were
treated with epinephrine and atropine infusion
(1 mg given every 3–5 min) and cardiac massage for
3 min, while VF and pulseless VT were treated with
primary DC cardioversion (biphasic; 150 J). Persist-
ent or recurrent VT or VF were treated by infusion
of NIF (0.15 mg/kg) and sequential cardiac massage
for 3 min before a pulse check. Further DC cardio-
version (150 J) was performed on patients with sus-
tained VT/VF. In the case of intractable VT/VF ad-
ditional NIF was administered. While NIF was be-
ing administered, the injection of epinephrine was
stopped in order to inhibit an increase in the IKs
current (IKs: the slow components of the delayed
rectifier potassium current). If successful defibril-
lation was achieved, continuous intravenous NIF
was infused as a preventive measure against the re-
currence of VT/VF. However, in patients with QT
prolongation it was not permissible for NIF to be
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used as a first-line drug, and therefore lidocaine
(LID) was the selected alternative.
Routine algorithms have not, on the other hand,
been developed for NIF-resistant VT/VF. A percu-
taneous cardiopulmonary support system (PCPS),
anti-tachycardia pacing by a temporary pacemaker,
anti-arrhythmic drugs and other agents, including
potassium chloride and sodium bicarbonate, were
administered at the discretion of the attending phy-
sician. In the LSGB cases the local anesthetic
agents, such as 0.5% LID, 0.25% bupivacaine, 1%
mepivacaine, or ropivacaine (75 mg), were select-
ed by the physician. The local anesthetic agent was
injected in a stepwise manner (5 cc + 5 cc) with
a 10 cc disposable syringe (23 G) into the basal part
of the left transverse process of the sixth cervical
spine (C6), taking care not to injure the left carotid
artery. LSGB is conventionally used in the disease
of the anesthesia department, and it is carried out
for the pain control of the headache or the peripheral
facial paralysis. It is one of the daily manual skills
for the anesthesiologist, and thus the technique of
LSGB is comparatively simple and easy for the crit-
ical care physician also.
As soon as CPR was initiated, blood specimens
were drawn from the femoral artery to determine
and correct the plasma potassium level (mEq/L), the
blood pH and the lactate levels.
Statistical analysis
All measurements were presented as means ±
± SD. For evaluating the statistical significance the
c2 test was used to test the differences between the
mean values obtained for the defibrillation success
and failure groups. P < 0.05 was considered to be
statistically significant.
Figure 1. Algorithm of cardiopulmonary resuscitation (CPR) for patients with out-of hospital cardiopulmonary arrest
(CPA) in Tokai University. Asystole and pulseless electrical activity (PEA) were treated with epinephrine and atropine
infusion (1 mg given over every 3–5 min) and cardiac massage for 3 min, whereas pulseless ventricular tachycardia
(VT) and fibrillation (VF) were treated with primary direct-current (DC) cardioversion (Biphasic, 150 J). Persistent or
recurrent VT or VF was treated by infusion of nifekalant hydrochloride (0.15 mg/kg) and sequential cardiac massage
for 3 min before a pulse check. Further DC cardioversion (150 J) was performed for patients with sustained VT/VF. In
the case of intractable VT/VF, additional nifekalant hydrochloride was administered up to 3 times. If successful
defibrillation was achieved, continuous intravenous nifekalant hydrochloride was infused as a preventive measure
against the recurrence of VT/VF. However if not, left stellate ganglion block (LSGB) or after treatment was performed;
*body weight 50 kg assumption; nifekalant hydrochloride 0.15 mg/kg conversion.
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Results
Defibrillation effect and mortality in the
LSGB group vs. the non-LSGB group (Fig. 2)
LSGB was performed in 11 patients (the LSGB
group), while in 4 patients it was not performed (the
non-LSGB group) (Fig. 2). In the LSGB group si-
nus rhythm was restored after the performance of
LSGB with the administration of NIF in 7 patients
(the “successful” cases), but was not restored in
4 patients (the “failed” cases). DC cardioversion
was required for all cases after LSGB, because si-
nus rhythm was not restored spontaneously by
LSGB alone. Six of the successful cases were ad-
mitted into hospital, but 1 patient died from recur-
rent VF, while defibrillation combined with LSBG
was unsuccessful in 4 patients, who eventually
died, 1 from VF and 3 from asystole. In the non-
LSGB group, in contrast, PCPS was used for
2 patients and procainamide was injected into an-
other 2 patients, but they did not respond to treat-
ment and died from VT/VF. Mortality after CPR
was 45% in the LSGB group and 100% in the non-
LSGB group.
Comparison of the characteristics of
the successful and failed cases in
the LSGB group (Table 1)
The 11 patients in the LSGB group were divid-
ed into two subgroups, namely the defibrillation suc-
cess cases and the defibrillation failure cases, to de-
termine the differences in CPR background. The
ejection fraction of the heart, which was evaluated
using echocardiography, was considered as the ref-
erence, because echocardiography was performed in
different situations in different individuals (the data
of the 7 successful patients were obtained after CPR,
while for 4 patients the data obtained before CPA was
substituted). The doses of drug administration were
indicated as the total amount required during CPR.
There were no significant differences between the
defibrillation success and failure cases with respect
to age, gender, ejection fraction, doses of epine-
phrine, LID, NIF, and LSGB or in the frequency of
DC cardioversion. Furthermore, the serum K+ lev-
els the arterial blood pH and the serum lactate did
not differ between the two groups. However, in the
defibrillation failure groups, we observed a tenden-
cy toward hyperkalemia and acidosis. Short-term
Figure 2. Defibrillation rate and mortality in the left stellate ganglion block group (LSGB group) and the non-LSGB
group. Direct-current (DC) cardioversion applications following LSGB lead to sinus rhythm in 7 patients but failed in
4 patients. One of the success cases died from the recurrence of ventricular fibrillation (VF), while 4 patients in the
LSGB group died from pulseless electrical activity. In the non-LSGB group, all patients died from VF. Mortality rate in
response to LSGB was significant lower than in the non-LSGB cases (45% vs. 100%); VT — ventricular tachycardia.
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survival was estimated by the admission rate to the
intensive care unit, and the long term prognosis was
evaluated by the Glasgow Outcome Scale. In the
defibrillation success cases by LSGB, both the short-
term and long-term prognoses were superior and
complete recovery was achieved by 2 patients (Ta-
ble 2: Case 1 and 6). LSGB was performed by a car-
diologist in 7 cases, by a critical care practitioner in
3 cases, and by the anesthesiologist in 1 case.
Background of the 11 patients in LSGB
group and the therapeutic outcome (Table 2)
The baseline characteristics of the 11 patients
with respect to the CPR implementation and the
therapeutic outcomes are shown in Table 2. Where
there was underlying disease, reference was made
to the patient’s record at our hospital, the primary
home doctor and information from the family. All
the 11 patients had primary cardiac disease, and
there was no exogenous factor related to CPA. The
underlying diseases included old myocardial infarc-
tion (OMI, 2 patients), acute myocardial infarction
(AMI, 3 patients), hypertrophic cardiomyopathy
(HCM, 2 patients), hypertension (HT, 2 patients),
dilated cardiomyopathy (DCM, 1 patient), chronic
heart failure (CHF) with severe aortic valve regur-
gitation (AR, 1 patient), and pulmonary hyperten-
sion (PH, 1 patient). The drug used for LSGB was
Table 1. Comparison of the characteristics of the “success” and “failure” cases in the group of LSGB.
Characteristics Success (n = 7) Failure (n = 4) P value
Age (years) 58±18.4 63±20.6 NS
Male 6/7 (86%) 3/4 (75%) NS
Ejection fraction (%) 47±14.2 34±25.4 NS
Dose of epinephrine [mg] 5±4.7 9±2.3 NS
Dose of lidocaine [mg] 29±48.8 33±57.7 NS
Dose of nifekalant [mg] 17±5.5 16±3.5 NS
Dose of LSGB [mg] 10±3.2 10±0.0 NS
Number of DC shocks 36±75.4 7±3.8 NS
Serum K+ level [mEq/L] 4.9±1.4 5.5±1.7 NS
Serum pH 7.25±0.15 7.13±0.15 NS
Serum lactate 75.1±54.3 77.3±19.4 NS
Admitted ICU 6/7 (86%) – –
Glasgow coma scale 3±1.7 – –
Values are means ± SD of defibrillation success and failure cases. Data were obtained during cardiopulmonary resuscitation and after successful
defibrillation; LSGB — left stellate ganglion block; DC — direct-current cardioversion; ICU — intensive care unit. Significant value p < 0.05
Table 2. Background of the 11 patients in LSGB group and the therapeutic outcome.
Patient Underlying Defibrillation LSGB/dose [ml] Diameter of [mm] Onset and VT/VF
no. disease success pupil (right/left) course  rate [bmp]
Pre Æ Post LSGB
1 OMI + B/10 + M/10 4/4 Æ 4/3 VT Æ VF Æ SR 230–250
2 AMI + B/10 4/4 Æ 4/3 VT Æ VF Æ SR 240–250
3 HCM + B/10 5/5 Æ 5/3 VT Æ VF Æ SR 200–220
4 HCM + L/10 + R/10 5/5 Æ 5/2 VT Æ VF Æ SR 240–280
5 AMI + B/10 6/6 Æ 6/3 VF Æ VT Æ SR 230–260
6 AMI + L/5 8/8 Æ 8/3 VF Æ SR 250–280
7 HT + B/10 8/8 Æ 8/3 VF Æ SR Æ Asystole 260–280
8 DCM – L/15 5/5 Æ 5/5 VF Æ PEA Æ Asystole 230–240
9 OMI – B/10 6/6 Æ 6/6 VF Æ PEA Æ Asystole 260–280
10 AR, CHF – R/10 5/5 Æ 5/5 VF Æ PEA Æ Asystole 260–280
11 PH – B/10 5/5 Æ 5/5 PEA Æ VF Æ Asystole 220–240
OMI — old myocardial infarction, AMI — acute myocardial infarction, HCM — hypertrophic cardiac myopathy, HT — hypertension, DCM — dilated
cardiac myopathy, AR — aortic valve regurgitation, CHF — chronic heart failure, PH — pulmonary hypertension, LSGB — left stellate ganglion block,
B — bupivacaine hydrochloride, M — mepivacaine hydrochloride, L — lidocaine hydrochloride, R — ropivacaine hydrochloride, VF — ventricular
fibrillation, VT — ventricular tachycardia; SR — sinus rythm; PEA — pulseless electrical activity
360
Cardiology Journal 2007, Vol. 14, No. 4
www.cardiologyjournal.org
ropivacaine hydrochloride in 2 cases, mepivacaine
hydrochloride in 1 case, lidocaine hydrochloride in
3 cases and bupivacaine hydrochloride in 7 cases
(including duplicate use). The therapy response of
LSGB was identical to one of the symptoms of
Horner’s syndrome. Prompt miosis of the left eye
suggested successful LSGB. The occurrence of ip-
silateral miosis was fortunately easy to recognise
since both pupils were quite dilated in the out-of-
hospital CPA patients before LSGB was performed.
One of the patients from the success group,
a 22-year-old male suffering from cardiomyopathy
was treated 207 times with DC cardioversion in
combination with PCPS. This was the first case of
LSGB in this study and was therefore performed
by a skilled anesthesiologist, and defibrillation was
finally successful. On the other hand, ipsilateral
miosis was never observed in any of the 4 cases in
the failed group. The reasons were thought to be
as follows. It was difficult to obtain the blocking
effect in 1 patient (Case 8) because of an anatomi-
cal change following cervical lymphadenectomy. In
2 other cases (Cases 9 and 10) sudden cardiac ar-
rest occurred following LSGB, and they never re-
verted to spontaneous circulation. The reason was
not clear, but the slight inotropic action of LSGB
may have had some effect, because these 2 patients
had severe heart failure owing either to OMI or
massive AR. The remaining 1 patient (Case 11)
showed the worst acidosis on arrival of all the cas-
es and a sinus suppression effect might have devel-
oped owing to the cross-interaction of LSGB under
conditions of acidosis. From these 4 cases, as for
LSGB, it appears that an unfavourable action may
possibly develop where there is severe cardiac dys-
function and acidosis.
An example of a case who demonstrated
complete recovery owing to the combined
therapy of NIF and LSGB (Fig. 3, 4)
In October 2006 an 82-year-old male with re-
current VT/VF was admitted to our Emergency
Department. Since he had a past history of CPA due
to MI, an implantable cardioverter-defibrillator
(ICD) had been inserted in another hospital. Prior
to his being transferred to our hospital, VT/VFs had
automatically been detected and ICD shocks actu-
ated 7 times. All these DC shocks had succeeded
in converting the sinus rhythm, and his circulatory
condition was therefore stable on arrival (Fig. 3A).
LID was used as a first-line drug because QT was
already slightly prolonged following the oral intake
of AMD (Fig. 3, upper panel of ECG). LID was ad-
ministered step by step (50 mg + additional 50 mg),
and sinus rhythm was restored temporarily (Fig. 3A).
NIF was then administered (0.15 mg/kg) as
a second-line agent, although its effect in preventing
VT/VF was also temporary. Soon afterwards VT/VF
recurred frequently and deteriorated into ES. Fol-
lowing the use of drug sedation (1% propofol) with
tracheal intubation, additional NIF (0.15 mg/kg) was
administered (Fig. 3B). Since the preventive effect
of sedation on VT/VF lasted only 30 min, LSGB was
performed by stepwise injection of 0.25% bupi-
vacaine (5 mg + additional 5 mg). Bupivacaine was
not sufficient to develop the blocking effect but,
owing to the change to 1% mepivacaine from bupi-
vacaine, sinus rhythm was soon restored. Although
VT/VF recurred after 1 hour, the combined thera-
py of LSGB using mepivacaine and NIF (0.15–
–0.3 mg/kg, i.v.) finally succeeded in maintaining si-
nus rhythm. Although the QTc-prolongation effect
of NIF was never obtained by a single administra-
tion of NIF along with sedation, the QTc was sig-
nificantly prolonged after administration of intrave-
nous NIF along with LSGB (Fig. 4).
Discussion
The major findings of the present study are as
follows: (1) the combined use of NIF and LSGB was
useful in the treatment of NIF-resistant VT/VF in
patients with out-of-hospital CPA (defibrillation ef-
fect: 64%, n = 11), (2) the admission rate and prog-
nosis were superior in the LSGB group compared
with the non-LSGB group, (3) there were no sig-
nificant differences in patient characteristics and
CPR content between the defibrillation success and
failure subgroups in the LSGB group.
Intravenous class III anti-arrhythmic
agents: differences between AMD and NIF
NIF is a pure IKr-channel blocker that was
originally developed by Mitsui Pharmaceutical Com-
pany, since the use of intravenous AMD is still not
allowed in Japan. AMD has established an immov-
able position as a first-line drug of CPR based on
AHA guidelines (evidence level: class IIb) in emer-
gency situations in all countries except Japan [13].
It is a multiple-channel blocker and has an ex-
tremely superior defibrillation effect by means of
its various pharmacological actions in addition to
the IKr-channel blocking action [14]. However, it
has also been reported that intravenous AMD had
side effects such as conduction disturbance and
hypotension caused by its calcium channel block-
ing, sodium channel blocking and beta blocking
actions [15].
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Post ICD implantation because of CPA (82 y/o. M)
AM 8:00 ~
On arrival
AM 8:25 ~
Post LID i.v.
AM 8:39 ~
Post NIF i.v.
A
B
AM 8:44 ~
ES
Ø
Sedation
+
Intubation
+
NIF i.v.
AM 9:52 ~
Post LSGB
AM 11:07 ~
Post NIF i.v.
+ LSGB
II ICD shock
II ICD shock
*Manual DC shock
Figure 3. Recordings of the electrocardiograph of implantable cardioverter-defibrillator (ICD) in patients with inferior
myocardial (MI) patient. Eighty two year old male with recurrent ventricular tachycardia/ventricular fibrillation (VT/VF) was
admitted to our emergency department. VT/VFs were automatically detected and ICD shocks were actuated 7 times.
Lidocaine (LID) was used as a first-line drug because QT was already slightly prolonged following oral intake of amiodarone
(AMD), and sinus rhythm was restored temporarily (A — middle panel). Then, nifekalant chydrohloride (NIF) was administe-
red as a second-line agent; however, its effect was also temporary (A — lower panel). Soon after, VT/VF deteriorated into
electrical storm (ES) (B — top panel). Following the use of drug sedation, additional NIF was administered. Then left stellate
ganglion block (LSGB) was performed, and sinus rhythm was restored, however its effect was for 60 min (B — middle
panel). Finally combined therapy of NIF and LSGB succeeded maintaining the sinus rhythm (B — lower panel).
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On the other hand NIF can be used for patients
with severe cardiac failure and hemodynamically
unstable VT/VF, since it has no negative chrono-
tropic and inotropic actions [1, 2]. From a rat mod-
el of heart failure it is known that NIF has a posi-
tive inotropic action through the sarcoplasmic re-
ticulum [16]. However, the disadvantage of NIF is
that a single use of NIF could not prolong the QT
in very rapid VF. The anti-arrhythmic action of NIF
depends upon the cycle length of VT/VF, which is
known as the reverse frequency dependence effect [3].
Therefore excessive QT prolongation accompanied
by bradycardia is potentially dangerous and can
cause torsades de pointes [17].
The above-mentioned, pharmacological action
is markedly different with AMD and NIF, although
they are the same potassium anti-arrhythmic
agents. For each medicine adequate knowledge is
needed of its concomitant agents and the indications
for its use.
The pharmacological effect
of NIF on CPA patients
In our previous study the defibrillation efficien-
cy of NIF was compared for patients with out-of-
Figure 4. Clinical time course of cardiopulmonary resuscitation (CPR). The upper panel shows the V3 lead of the
echocardiograph. The QTc-prolongation effect of nifekalant (NIF) was not obtained by a single application of NIF with
sedation, but QTc was significantly prolonged following the combined use of NIF and left stelle ganglion block (LSGB).
The middle panel shows the fluctuations in RR intervals, QTc intervals, and serum potassium (K+) levels. The lower
panel shows the schema of the clinical time course (transverse axis) of CPR from the time of arrival to admission.
-hospital CPA and in-hospital CPA. We observed that
the defibrillation efficiency was slightly lower in the
out-of-hospital cases than in the in-hospital cases
(75% vs. 89%) and the QTc prolongation effect in
out-of-hospital CPA was less than that in in-hospi-
tal CPA (mean QTc, 0.43 ms vs. 0.6 ms) [7]. It was
difficult to inhibit the IKr currents completely in
out-of-hospital CPA because of sympathetic hyper-
tonia by large doses of epinephrine, severe acido-
sis and hyperkalemia. As shown in Figure 4, be-
cause of the occurrence of ES sympathetic hyper-
tonia never provided the QTc-prolongation effect
by a single application of NIF even under sedation.
However LSGB could enhance the effect of NIF by
reducing the sympathetic tone relatively. It should
be noted that NIF was never administered exclu-
sively until QT had been prolonged, since the
threshold of that curative effect and the drug toxic-
ity of NIF might be in abutment with each other in
out-of-hospital CPA. There is a report that the oc-
currence of torsade de pointes induced by NIF in
humans was due not only to excessive QT prolon-
gation but also to the increase in transmural disper-
sion of repolarisation (TDR) [17]. In other words,
there is a possibility that TDR might be increased
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where there has been overdosage of NIF, even if
QTc is not prolonged. In addition, from the basic
studies using normal rabbit hearts one of the defi-
brillation mechanisms of NIF was explained as the
destabilisation effect of the excitement making it
difficult to maintain the re-entrant circuit of
VT/VF [5]; in other words, NIF not only possesses
a strong anti-arrhythmic action but also poses the
risk of furthering VF or its recurrence. However,
the simultaneous use of NIF and DC cardioversion
can aid the termination of VF and prevent the gen-
eration of new re-entrant circuits.
Which is better as a sympathetic blockade,
intravenous beta-blocker or LSGB?
A stellate ganglion (SG) is one of the cervical
sympathetic trunks and is divided into superior,
middle, and inferior cervical ganglions. An SG or-
ganises and controls the preganglionic fibres of the
head, face, neck, arms and chest, along with the
cardiac sympathetic supply that innervates the sur-
face of the ventricles [18]. It is known that hetero-
geneous sympathetic innervation is related to the
generation of ventricular arrhythmias and sudden
cardiac death [19]. VT/VF could be induced in dogs
with MI by administration of the nerve growth fac-
tor into the LSG; furthermore, the pathological anal-
ysis of excessive sympathetic nerve sprouting
might be related to sudden cardiac death [20]. More-
over, it has been revealed that resection of the SG
in normal cats significantly reduced the incidence
and mortality of VT/VF [21].
There are two methods commonly used for
a sympathetic blockade; LSGB or intravenous beta-
blocker injection. In in vivo experiment propranolol
infusion decreased VT/VF vulnerability owing to
the attenuation of denervation supersensitivity in
dogs after 1–2 weeks of MI [22], while in an ex-
tremely acute ischemic model by ligation in dogs
dispersion of the refractory period between the
ischemic and non-ischemic zones was not reduced
by propranolol injection [23]. As for the advantage
of an intravenous injection, if the circulatory defect
has been sufficiently reversed, it may protect
against the effect of deterioration of sympathetic
nerve activity on electrical instability during
ischemia because a sympathetic blockade effect can
be comparatively uniform and little affected by the
unevenness of distribution of a cardiac nerve. How-
ever, the CPA patient has been under conditions of
significant terminal heart failure caused by severe
extensive ischemia and sinus suppression because
of overwhelming acidosis. The intravenous admin-
istration of propranolol is difficult, since it has
stronger inotropic and chronotropic actions than
LSGB. The absence of inotropic and chronotropic
actions is an advantage of LSGB [12], and therefore
it is available for use in CPR. The local sympathet-
ic nerves distributed over the left ventricle are
specifically blocked [18]. This makes the cardiac
response faster and may promote cardiac effects
without producing hemodynamic deterioration.
The efficacy of LSGB and/or NIF with respect
to the repolarisation of the left ventricle
Changes in the local dispersion of activation
recovery intervals (ARI-Ds) using rabbit hearts that
had undergone sympathetic denervation have been
investigated by one of the present authors. It was
observed that ARI-Ds were significantly increased
by the stimulation of LSG in comparison with in-
travenous beta-stimulants [24]. We hypothesised
that LSGB could decrease ARI-Ds, larger than in-
tervenous beta-blocker, and as results, improve the
regional conduction block in an ischemic heart. In
a healthy volunteer the QT and QTc intervals were
shortened, but the RR interval and QT dispersion
(QT-D) were not altered by LSGB [25]. The resec-
tion of the thoracic sympathetic trunk in a patient
with congenital long QT syndrome significantly de-
creased the QT-D without QT shortening [26]. We
speculate that if QT has been excessively extend-
ed by the effect of NIF, LSGB may have the poten-
tial to correct the QT-D in the drug-induced long
QT syndrome.
Blockade of the right stellate ganglion (RSGB)
is never recommended for patients with heart disease
because of its proarrhythmic effects. In an experimen-
tal model the occurrence of episodes of VT/VF was
increased by RSGB in occlusion-induced arrhythmi-
as [9]. Even in a healthy volunteer, RSGB produced
RR shortening, QT prolongation and exacerbation of
QT-D [25] and fluctuations of the vagal tone [27]. The
difference between the reactivities of the LSGB and
RSGB are thought to be influenced by the expression
of beta receptors, the innervation of the sinus node
from the RSG and infiltration anesthesia to the cardi-
ac branch of the vagal nerve [27, 28].
As regards electrophysiological examination of
NIF, we previously investigated the action poten-
tial duration (APD) prolongation effect of NIF us-
ing a normal rabbit and reported that NIF decreased
the APD dispersion by increasing the homogene-
ous APD at the surface of the heart [29]. While in
the in vivo experiment using CPA model due to VT/
/VF induction in MI dogs, intravenous NIF im-
proved TDR owing to the ARI prolongation of the
mid-layer of the left ventricle [30].
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From these considerations it appears that the
combination of NIF and LSGB has the potential to
promote the homogenization of the electrical insta-
bility in a diseased heart; nevertheless, further ex-
periments are required for a greater understanding
of this therapy.
Conclusion
The combination therapy of intravenous NIF
and LSGB was useful in defibrillating intractable
VT/VF. The applicability of LSGB for the treatment
of refractory VT/VF is not common. It is, however,
a potentially innovative treatment strategy for IKr-
-channel blocker resistant VT/VF.
Study limitations
It was impossible to evaluate RR intervals, QT
intervals, QTc intervals and QT-D since with the
exception of cases 1 and 4 the ECGs of the patients
had revealed VT/VF from the time of arrival until
the time of successful defibrillation by LSGB. In
cases 1 and 4 LSGB was performed for ES after
sedation and therefore the ECG parameters had to
be evaluated while keeping in mind the effects of
intravenous anesthetic agents.
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